佛慈制药(002644) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥236,625,666.66, a decrease of 14.68% compared to the same period last year[5] - Net profit attributable to shareholders was ¥1,640,394.58, down 92.61% year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥2,433,309.54, a decline of 112.53% compared to the previous year[5] - Total operating revenue for the third quarter of 2022 was CNY 698.41 million, an increase of 5.5% compared to CNY 664.17 million in the same period last year[21] - Net profit for the third quarter of 2022 was CNY 53.19 million, a decrease of 25% from CNY 70.81 million in the previous year[22] - Earnings per share for the third quarter of 2022 were CNY 0.1035, down from CNY 0.1386 in the same period last year[23] Cash Flow and Liquidity - Cash flow from operating activities showed a net outflow of -¥57,205,628.31, a decrease of 174.13% compared to the previous period[12] - The company reported a decrease in cash and cash equivalents to ¥278,718,540.89 from ¥374,940,257.22, a decline of approximately 25.7%[17] - The net cash flow from investment activities was -76,459,873.37 CNY, with cash inflows totaling 76,195,763.46 CNY and outflows of 152,655,636.83 CNY[25] - The net cash flow from financing activities was -88,029,759.83 CNY, with cash inflows of 7,930,885.95 CNY and outflows of 95,960,645.78 CNY[25] - The net increase in cash and cash equivalents for the period was -87,316,643.37 CNY, resulting in an ending balance of 324,713,879.88 CNY[25] - The beginning cash and cash equivalents balance was 412,030,523.25 CNY, which decreased to 324,713,879.88 CNY by the end of the period[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,385,127,636.54, representing a 1.40% increase from the end of the previous year[5] - The company's total liabilities decreased to CNY 705.12 million from CNY 724.59 million year-over-year[22] - Total current liabilities increased to ¥384,400,110.28 from ¥374,838,677.06, showing a rise of about 2.3%[18] - The total cash outflow for investment activities was 152,655,636.83 CNY, with 39,869,200.33 CNY spent on fixed assets and intangible assets[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,961[13] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of shares, totaling 314,713,676 shares[13] - Total equity attributable to shareholders of the parent company increased to CNY 1.67 billion from CNY 1.61 billion in the previous year[22] Research and Development - Research and development expenses increased by 36.02% to ¥14,343,482.37, reflecting the company's commitment to enhancing R&D efforts[11] - Research and development expenses for the third quarter of 2022 were CNY 14.34 million, an increase of 36% from CNY 10.55 million in the same period last year[21] - The company reported a significant increase in long-term deferred expenses by 775.67% to ¥7,828,335.12 due to new R&D projects[10] Market and Future Outlook - The company has not disclosed any new product or technology developments in the current report[15] - There are no indications of market expansion or mergers and acquisitions mentioned in the current report[15] - The company has not provided specific future guidance or outlook in the current report[15] - The company plans to continue expanding its market presence and invest in new product development to drive future growth[22] Inventory and Receivables - Accounts receivable rose by 30.25% to ¥330,769,663.59, primarily due to the expansion into new markets and new customers[10] - Inventory as of September 30, 2022, is ¥288,767,946.08, compared to ¥258,831,694.16 at the start of the year, indicating an increase of about 11.6%[17] - Accounts receivable increased to ¥330,769,663.59 as of September 30, 2022, up from ¥253,945,827.17 at the beginning of the year, representing a growth of approximately 30.3%[17]